New figures from MS Ireland show increased demand for the organisation’s services in the first quarter of this year.
MS Ireland is calling on the government to improve access to treatments for people with MS such as Tysabri and Gilenya. The organisation says that the drugs are “widely available” to MS sufferers in other EU countries and are used to treat relapsing-remitting MS.
Tarragh Donohoe of MS Ireland told TheJournal.ie that both drugs are considered ‘second-line’ treatment and that if people with MS are not taking those, then it’s likely they’re not getting any treatment at all.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/2325
- Similar Topics
- Last post